Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BND020
MIFTS: 61

Bone Disease

Categories: Bone diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Disease

About this section

MalaCards integrated aliases for Bone Disease:

Name: Bone Disease 12 15
Bone Diseases 55 43 44 73
Disorder of Skeletal System 73
Skeletal Disorder 55
Skeletal Disease 12

Classifications:

MalaCards categories:
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0080001
ICD10 33 M89.9 M89 M89.8
MeSH 44 D001847
SNOMED-CT 68 76069003
Sources

Summaries for Bone Disease

About this section
MedlinePlus : 43 Your bones help you move, give you shape and support your body. They are living tissues that rebuild constantly throughout your life. During childhood and your teens, your body adds new bone faster than it removes old bone. After about age 20, you can lose bone faster than you make bone. To have strong bones when you are young, and to prevent bone loss when you are older, you need to get enough calcium, vitamin D, and exercise. You should also avoid smoking and drinking too much alcohol. Bone diseases can make bones easy to break. Different kinds of bone problems include Low bone density and osteoporosis, which make your bones weak and more likely to break Osteogenesis imperfecta makes your bones brittle Paget's disease of bone makes them weak Bones can also develop cancer and infections Other bone diseases, which are caused by poor nutrition, genetics, or problems with the rate of bone growth or rebuilding NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Bone Disease, also known as bone diseases, is related to ischemic bone disease and osteopetrosis, and has symptoms including back pain, bone pain and sciatica. An important gene associated with Bone Disease is DANCR (Differentiation Antagonizing Non-Protein Coding RNA), and among its related pathways/superpathways are RANK Signaling in Osteoclasts and Osteoclast differentiation. The drugs AT-101 and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and prostate, and related phenotypes are cellular and growth/size/body region

Disease Ontology : 12 A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function.

Wikipedia : 76 Bone disease refers to the medical conditions which affect the... more...

Sources

Related Diseases for Bone Disease

About this section

Diseases related to Bone Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 373)
# Related Disease Score Top Affiliating Genes
1 ischemic bone disease 33.6 ACP5 BGLAP PTH RUNX2 SOST TNFRSF11A
2 osteopetrosis 33.1 CTSK TNFRSF11A TNFSF11
3 paget disease of bone 5, juvenile-onset 32.8 CALCA TNFRSF11A TNFRSF11B TNFSF11
4 osteitis fibrosa 32.4 B2M BGLAP CALCA PTH
5 paget's disease of bone 32.3 ACP5 B2M BGLAP CALCA PTH TNFRSF11A
6 hypophosphatasia 31.9 ALPL ALPP RUNX2
7 osteochondrodysplasia 31.9 ALPL BGLAP FGFR3
8 osteonecrosis 31.8 ACP5 BGLAP PTH RUNX2 TNFRSF11B TNFSF11
9 primary hyperparathyroidism 31.8 ALPP BGLAP CALCA FGF23 PTH VDR
10 chronic kidney failure 31.8 B2M BGLAP CALCA FGF23 PTH TNFRSF11B
11 renal osteodystrophy 31.7 BGLAP CALCA FGF23 PTH SOST TNFRSF11B
12 multicentric carpotarsal osteolysis syndrome 31.6 BGLAP CTSK TNFRSF11A TNFRSF11B TNFSF11
13 osteopetrosis, autosomal recessive 7 31.4 TNFRSF11A TNFSF11
14 cleidocranial dysplasia 31.4 ALPL BGLAP RUNX2
15 hypophosphatasia, adult 31.4 ALPL BGLAP CALCA PTH
16 arthropathy 31.3 B2M TNFRSF11B TNFSF11
17 osteopetrosis, autosomal dominant 2 31.3 ACP5 BGLAP CTSK SOST TNFSF11
18 bone inflammation disease 31.3 ACP5 BGLAP CTSK TNFRSF11B TNFSF11
19 enchondromatosis, multiple, ollier type 31.2 ACP5 EXT1 EXT2
20 myeloma, multiple 30.9 B2M DKK1 EXT1 FGFR3 TNFRSF11B TNFSF11
21 bone remodeling disease 30.6 ACP5 BGLAP CALCA CTSK EXT1 EXT2
22 kidney disease 30.5 B2M FGF23 PTH TNFRSF11B VDR
23 hyperparathyroidism 30.4 ACP5 BGLAP CALCA FGF23 PTH TNFRSF11B
24 rickets 30.2 ALPL BGLAP FGF23 PTH VDR
25 osteomalacia 30.2 ALPL BGLAP CALCA FGF23 PTH VDR
26 hypophosphatemia 30.2 BGLAP FGF23 PTH
27 idiopathic hypercalciuria 30.1 BGLAP TNFSF11 VDR
28 parathyroid adenoma 30.1 BGLAP CALCA PTH VDR
29 uremia 30.0 B2M PTH TNFRSF11B VDR
30 osteoporosis 30.0 ACP5 ALPL ALPP BGLAP CALCA CTSK
31 fibrous dysplasia 30.0 BGLAP CALCA FGF23
32 hypoparathyroidism 29.9 ALPP BGLAP FGF23 PTH
33 secondary hyperparathyroidism of renal origin 29.9 ACP5 BGLAP CALCA FGF23 PTH TNFRSF11B
34 monoclonal gammopathy of uncertain significance 29.9 B2M DKK1 FGFR3
35 bone resorption disease 29.9 ACP5 BGLAP CALCA CTSK DKK1 PTH
36 rheumatoid arthritis 29.8 ACP5 CTSK TNFRSF11A TNFRSF11B TNFSF11
37 hyperostosis 29.8 FGF23 SOST TNFRSF11B
38 hyperphosphatemia 29.8 FGF23 PTH RUNX2 VDR
39 osteomyelitis 29.6 ACP5 CTSK TNFSF11
40 giant cell tumor 29.6 BGLAP CALCA CTSK TNFRSF11A TNFRSF11B TNFSF11
41 al amyloidosis 29.6 B2M CTSK
42 glucocorticoid-induced osteoporosis 29.5 ACP5 BGLAP CALCA DKK1 PTH RUNX2
43 polycystic bone disease 12.1
44 hypophosphatemic bone disease 12.1
45 brittle bone disorder 11.8
46 gorham's disease 11.7
47 cystic angiomatosis of bone, diffuse 11.2
48 col1a1/2-related osteogenesis imperfecta 11.2
49 diaphanospondylodysostosis 11.1
50 inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 1 11.0

Graphical network of the top 20 diseases related to Bone Disease:



Diseases related to Bone Disease
Sources

Symptoms & Phenotypes for Bone Disease

About this section

UMLS symptoms related to Bone Disease:


back pain, bone pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Disease:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ALPL B2M CTSK DKK1 EXT1 FGFR3
2 growth/size/body region MP:0005378 10.3 ALPL B2M CTSK DKK1 EXT1 FGF23
3 craniofacial MP:0005382 10.25 ALPL CTSK DKK1 EXT1 FGFR3 PTH
4 homeostasis/metabolism MP:0005376 10.18 ALPL B2M CTSK DKK1 FGF23 FGFR3
5 hematopoietic system MP:0005397 10.17 ALPL B2M CTSK FGF23 FGFR3 PTH
6 digestive/alimentary MP:0005381 10.15 ALPL B2M CTSK EXT1 FGF23 FGFR3
7 endocrine/exocrine gland MP:0005379 10.13 ALPL B2M CTSK FGF23 PTH RUNX2
8 immune system MP:0005387 10.11 ALPL B2M CTSK FGF23 FGFR3 PTH
9 limbs/digits/tail MP:0005371 10.07 ALPL CTSK DKK1 EXT1 FGF23 FGFR3
10 mortality/aging MP:0010768 9.97 ALPL B2M DKK1 EXT1 EXT2 FGF23
11 integument MP:0010771 9.92 B2M EXT1 FGF23 FGFR3 RUNX2 TNFRSF11A
12 respiratory system MP:0005388 9.56 ALPL CTSK DKK1 FGF23 FGFR3 RUNX2
13 skeleton MP:0005390 9.47 ALPL CTSK DKK1 EXT1 EXT2 FGF23
Sources

Drugs & Therapeutics for Bone Disease

About this section

Drugs for Bone Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1038)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
AT-101 Approved, Investigational Phase 4,Phase 3 90141-22-3, 652-67-5 12597
2
Nitric Oxide Approved Phase 4,Phase 3 10102-43-9 145068
3
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3 87-33-2 6883
4 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
6
Emtricitabine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 143491-57-0 60877
7
Alendronate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 66376-36-1, 121268-17-5 2088
8
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 471-34-1
9
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 137-58-6 3676
10
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113775-47-6 68602 5311068
11
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
12
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
13 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
14
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 57-83-0 5994
15
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
16
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
17
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
18
Etidronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7414-83-7, 2809-21-4 3305
19
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 302-25-0
20
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-24-8 5755
21
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 2921-57-5
22
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 83-43-2 6741
23
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
24
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
25
Thrombin Approved, Investigational Phase 4
26
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
27
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
28
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
29
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52232-67-4 16133850
30
Linagliptin Approved Phase 4 668270-12-0 10096344
31
Pioglitazone Approved, Investigational Phase 4,Not Applicable 111025-46-8 4829
32
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83150-76-9 383414 6400441
33
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
34
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
35 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
36
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
37
Etanercept Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 185243-69-0
38
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 599-79-1 5353980 5359476
39
Adalimumab Approved Phase 4,Phase 3,Phase 2,Not Applicable 331731-18-1 16219006
40
Mecasermin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68562-41-4
41
Pamidronate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 40391-99-9 4674
42
Rifampicin Approved Phase 4,Phase 3,Early Phase 1 13292-46-1 5458213 5381226
43
Pyrazinamide Approved, Investigational Phase 4,Early Phase 1 98-96-4 1046
44
Ethambutol Approved Phase 4 74-55-5 3279 14052
45
Isoniazid Approved, Investigational Phase 4,Phase 3,Early Phase 1 54-85-3 3767
46
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
47
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
48
Racepinephrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 329-65-7 838
49
Clonidine Approved Phase 4,Phase 3,Not Applicable 4205-90-7 2803
50
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 4762)
# Name Status NCT ID Phase Drugs
1 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
2 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
3 Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients Unknown status NCT00889629 Phase 4 Doxercalciferol;placebo
4 Intravenous Paricalcitol in Chronic Hemodialysis Patients Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
5 A Prospective Study of the InterFuse T(tm), Unknown status NCT02678130 Phase 4
6 Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
7 The Effect of Perioperative Lidocaine Intravenous Infusion on Postoperative Recovery After Spine Surgery. Unknown status NCT02762656 Phase 4 Lidocaine
8 The Effect of Dexmedetomidine Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia Unknown status NCT02535273 Phase 4 Dexmedetomidine;Lidocaine;Low-dose Dexmedetomidine;Moderate-dose Dexmedetomidine;High-dose Dexmedetomidine;normal saline
9 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Unknown status NCT02535000 Phase 4 Duloxetine;Placebo
10 Post-Market Surveillance Study of the TM Ardis Interbody Fusion System Unknown status NCT02429908 Phase 4
11 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
12 The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
13 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
14 Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis Unknown status NCT01675297 Phase 4 Risedronate/Cholecalciferol combination;Risedronate
15 CERAMENTâ„¢|G - Bone Healing and Re-infection Prophylaxis Unknown status NCT02128256 Phase 4
16 Osteoporosis and Dental Implant Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
17 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
18 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
19 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4 Alendronate
20 A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery Unknown status NCT02206685 Phase 4 Methadone;Normal Saline
21 Effect of Human Thrombin With Gelatin Matrix on Perioperative Blood Loss in Scoliosis Surgery Unknown status NCT01451788 Phase 4
22 Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum Unknown status NCT01486953 Phase 4 Desflurane;Sevoflurane
23 Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
24 Effect of Evogliptin on Bone Metabolism in Human Unknown status NCT02587975 Phase 4 Evogliptin
25 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
26 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
27 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Unknown status NCT02976675 Phase 4
28 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Unknown status NCT02908958 Phase 4
29 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
30 Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
31 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
32 Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
33 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
34 Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
35 The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis Unknown status NCT02477852 Phase 4 Isoniazid;Rifampicin;Ethambutol;Pyrazinamide
36 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
37 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
38 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
39 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
40 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
41 Danish Multicenter Study of Adalimumab in Spondyloarthritis Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
42 Hip Scope Fascia-iliaca (FI) Block Study Unknown status NCT02365961 Phase 4 ropivicaine;clonidine;Epinephrine;Noropin
43 Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Unknown status NCT02364479 Phase 4 etanercept;etanercept (half dose);placebo
44 Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy Unknown status NCT02414698 Phase 4 TESI
45 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
46 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
47 Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy Unknown status NCT01204008 Phase 4
48 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
49 Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients Completed NCT02853539 Phase 4 Denosumab
50 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate

Search NIH Clinical Center for Bone Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: bone diseases

Sources

Genetic Tests for Bone Disease

About this section
Sources

Anatomical Context for Bone Disease

About this section

MalaCards organs/tissues related to Bone Disease:

41
Bone, Kidney, Prostate, Bone Marrow, Liver, Skin, Lung
Sources

Publications for Bone Disease

About this section

Articles related to Bone Disease:

(show top 50) (show all 1568)
# Title Authors Year
1
Are Bone Disease and Cardiovascular Disease Risk Correlated in an HIV Cohort? ( 29905594 )
2018
2
What does vanishing bone disease look like? ( 29572373 )
2018
3
Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease. ( 29668535 )
2018
4
Drug-eluting implants for the suppression of metastatic bone disease: current insights. ( 29561689 )
2018
5
Therapeutic effects of the novel subtype-selective histone deacetylase (HDAC) inhibitor chidamide on myeloma-associated bone disease. ( 29773595 )
2018
6
Feasibility of quantitative ultrasonography for the detection of metabolic bone disease in preterm infants - systematic review. ( 29907939 )
2018
7
Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction. ( 29365190 )
2018
8
Early TGF-I^ inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner. ( 29753718 )
2018
9
Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients. ( 29520605 )
2018
10
Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue. ( 29928372 )
2018
11
Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. ( 29492624 )
2018
12
Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment. ( 29435659 )
2018
13
Early Improvement in Pain and Functional Outcome but Not Quality of Life After Surgery for Metastatic Long Bone Disease. ( 29529637 )
2018
14
Impact of Early Versus Late Diuretic Exposure on Metabolic Bone Disease and Growth in Premature Neonates. ( 29491749 )
2018
15
Classical metaphyseal lesions thought to be pathognomonic of child abuse are often artifacts or indicative of metabolic bone disease. ( 29685201 )
2018
16
Regulation of breast cancer induced bone disease by cancer-specific IKKI^. ( 29662632 )
2018
17
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. ( 29748441 )
2018
18
Hyperparathyroidism Mimicking Metastatic Bone Disease: A Case Report and Review of Literature. ( 29446693 )
2018
19
WITHDROWN: Osteonecrosis of the jaw in patients traited by denosumab for malignant bone disease: Descriptive study on 9 cases ( 29680853 )
2018
20
Bone disease in β thalassemia patients: past, present and future perspectives. ( 28987275 )
2018
21
Bone-Targeted Therapies in Cancer-Induced Bone Disease. ( 29079995 )
2018
22
The Proteasome and Myeloma-Associated Bone Disease. ( 29080972 )
2018
23
A Study of the Relationship Between Cystatin C and Metabolic Bone Disease in Preterm Infants ( 29082894 )
2018
24
Bone Disease in Axial Spondyloarthritis. ( 29090349 )
2018
25
Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease. ( 29098360 )
2018
26
New agents in the Treatment of Myeloma Bone Disease. ( 29098361 )
2018
27
Biology and treatment of myeloma related bone disease. ( 29175022 )
2018
28
Outcomes of standardised approach to metabolic bone disease of prematurity. ( 29292538 )
2018
29
Patient survival following joint replacement due to metastatic bone disease - comparison of overall patient and prostheses survival between cohorts treated in two different time-periods. ( 29293034 )
2018
30
Pathogenesis of bone disease in multiple myeloma: from bench to bedside. ( 29330358 )
2018
31
Recent Trends and Advances in Cancer-Induced Bone Disease. ( 29340743 )
2018
32
Imaging of metabolic bone disease. ( 29350648 )
2018
33
Comparative analysis of conventional and biological treatment in healing of bone disease. ( 29379374 )
2018
34
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. ( 29429912 )
2018
35
Denosumab for myeloma bone disease: ready for prime time? ( 29429916 )
2018
36
Incidence of metabolic bone disease in preterm infants of birth weight <1250 g and in those suffering from bronchopulmonary dysplasia. ( 29460805 )
2018
37
Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease. ( 29473714 )
2018
38
CORR Insights®: Early Improvement in Pain and Functional Outcome but Not Quality of Life After Surgery for Metastatic Long Bone Disease. ( 29529638 )
2018
39
ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. ( 29924867 )
2018
40
Black Bone Disease of the Foot: A Two-Year Follow-Up Case Study. ( 30001940 )
2018
41
Bone Disease in Mastocytosis. ( 30007462 )
2018
42
Technical feasibility, radiation dosimetry and clinical use of 18F-sodium fluoride (NaF) in evaluation of metastatic bone disease in pediatric population. ( 30019285 )
2018
43
Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm. ( 30023010 )
2018
44
Can patient-specific finite element models better predict fractures in metastatic bone disease than experienced clinicians?: Towards computational modelling in daily clinical practice. ( 30034797 )
2018
45
A scoping review on the surgical management of metastatic bone disease of the extremities. ( 30081884 )
2018
46
PROMIS® scores in operative metastatic bone disease patients: A multicenter, prospective study. ( 30114336 )
2018
47
Advanced Imaging of Multiple Myeloma Bone Disease. ( 30131767 )
2018
48
Massive Osteolysis in Distal Shaft of Humerus: A Case Report on Vanishing Bone Disease. ( 30173685 )
2018
49
New diagnostic modalities and emerging treatments for neonatal bone disease. ( 30190174 )
2018
50
Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community. ( 30191258 )
2018
Sources

Variations for Bone Disease

About this section

ClinVar genetic disease variations for Bone Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CACNA1G NM_198382.2(CACNA1G): c.667_669delTTC (p.Phe223del) deletion Likely pathogenic rs730882202 GRCh38 Chromosome 17, 50571958: 50571960
2 CACNA1G NM_198382.2(CACNA1G): c.667_669delTTC (p.Phe223del) deletion Likely pathogenic rs730882202 GRCh37 Chromosome 17, 48649319: 48649321
3 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh37 Chromosome 11, 47433573: 47433573
4 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh38 Chromosome 11, 47412022: 47412022

Copy number variations for Bone Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 43764 10 49062854 52062367 Duplication skeletal anomalies
Sources

Expression for Bone Disease

About this section
Search GEO for disease gene expression data for Bone Disease.
Sources

Pathways for Bone Disease

About this section

Pathways related to Bone Disease according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
RANK Signaling in Osteoclasts 64
Show member pathways
 12.25 ACP5 CTSK TNFRSF11A TNFRSF11B TNFSF11
2
Osteoclast differentiation 37
11.87 ACP5 CTSK TNFRSF11A TNFRSF11B TNFSF11
3
Parathyroid hormone synthesis, secretion and action 37
11.83 BGLAP FGF23 PTH RUNX2 SOST TNFSF11
4
Rheumatoid arthritis 37
11.69 ACP5 CTSK TNFRSF11A TNFSF11
5
Endochondral Ossification 1
11.52 ALPL FGFR3 PTH RUNX2
6
FGF signaling pathway 1
11.33 BGLAP FGF23 RUNX2
7
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.31 BGLAP PTH RUNX2 TNFSF11 VDR
8
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.88 BGLAP CALCA PTH RUNX2 TNFRSF11A TNFRSF11B
9
NOTCH1 regulation of human endothelial cell calcification 1
10.78 ALPL FGFR3
10
Osteoclast Signaling 1
10.76 ACP5 CTSK TNFRSF11A TNFRSF11B TNFSF11
11
Thiamine metabolism 37
10.71 ALPL ALPP
12
Osteoblast Signaling 1
10.5 BGLAP FGF23 PTH TNFRSF11B TNFSF11
13
Vitamin D Metabolism 1
10.49 PTH VDR
Sources

GO Terms for Bone Disease

About this section

Cellular components related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ALPL B2M BGLAP CALCA CTSK DKK1
2 extracellular space GO:0005615 9.36 ALPL B2M BGLAP CALCA CTSK DKK1

Biological processes related to Bone Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.96 B2M BGLAP PTH TNFRSF11B
2 cell-cell signaling GO:0007267 9.88 CALCA FGFR3 PTH TNFRSF11A
3 regulation of signaling receptor activity GO:0010469 9.85 CALCA DKK1 FGF23 PTH TNFRSF11B TNFSF11
4 osteoblast differentiation GO:0001649 9.81 ALPL BGLAP RUNX2
5 cellular calcium ion homeostasis GO:0006874 9.8 CALCA PTH VDR
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.74 TNFRSF11A TNFRSF11B TNFSF11
7 monocyte chemotaxis GO:0002548 9.71 CALCA TNFRSF11A TNFSF11
8 bone mineralization GO:0030282 9.69 BGLAP FGFR3 PTH
9 osteoblast development GO:0002076 9.66 BGLAP RUNX2
10 positive regulation of bone resorption GO:0045780 9.65 TNFRSF11A TNFSF11
11 heparan sulfate proteoglycan biosynthetic process GO:0015012 9.65 EXT1 EXT2
12 endochondral ossification GO:0001958 9.65 ALPL FGFR3 RUNX2
13 mammary gland alveolus development GO:0060749 9.64 TNFRSF11A TNFSF11
14 regulation of osteoclast differentiation GO:0045670 9.62 BGLAP TNFSF11
15 negative regulation of bone resorption GO:0045779 9.62 CALCA TNFRSF11B
16 response to inorganic substance GO:0010035 9.61 BGLAP TNFRSF11B
17 response to magnesium ion GO:0032026 9.61 FGF23 TNFRSF11B
18 vitamin D metabolic process GO:0042359 9.6 FGF23 VDR
19 cellular response to vitamin D GO:0071305 9.59 BGLAP FGF23
20 cellular response to parathyroid hormone stimulus GO:0071374 9.58 FGF23 SOST
21 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process GO:0015014 9.56 EXT1 EXT2
22 skeletal system development GO:0001501 9.56 ALPL BGLAP EXT1 FGFR3 PTH RUNX2
23 phosphate ion homeostasis GO:0055062 9.55 FGF23 PTH
24 TNFSF11-mediated signaling pathway GO:0071847 9.52 TNFRSF11A TNFSF11
25 negative regulation of ossification GO:0030279 9.5 CALCA DKK1 SOST
26 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.49 FGF23 VDR
27 cellular polysaccharide biosynthetic process GO:0033692 9.46 EXT1 EXT2
28 bone resorption GO:0045453 9.46 ACP5 CTSK PTH TNFSF11
29 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.43 TNFRSF11A TNFSF11
30 response to vitamin D GO:0033280 9.43 ALPL BGLAP PTH
31 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.4 TNFRSF11A TNFSF11
32 ossification GO:0001503 9.23 ACP5 BGLAP EXT1 EXT2 RUNX2 SOST
33 cell differentiation GO:0030154 10.11 EXT2 FGF23 FGFR3 RUNX2 TNFSF11 VDR

Molecular functions related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alkaline phosphatase activity GO:0004035 9.26 ALPL ALPP
2 heparan sulfate N-acetylglucosaminyltransferase activity GO:0042328 9.16 EXT1 EXT2
3 glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity GO:0050508 8.96 EXT1 EXT2
4 N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity GO:0050509 8.62 EXT1 EXT2
Sources

Sources for Bone Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....